Definition
A hepatitis A vaccine is a biologically derived preparation administered to stimulate an immune response that confers protection against infection by the hepatitis A virus (HAV), a hepatotropic RNA virus that causes acute viral hepatitis.
Overview
Hepatitis A vaccines are part of routine immunization programs in many countries and are recommended for travelers to endemic regions, individuals at increased risk of exposure (e.g., men who have sex with men, drug users), and for outbreak control. The vaccine is typically delivered by intramuscular injection and provides long‑term immunity, with protection lasting at least 15–20 years after a complete series. Commercially available formulations include inactivated whole‑virus preparations and recombinant subunit vaccines derived from the HAV capsid protein.
Etymology/Origin
The term combines “hepatitis A,” denoting the first identified type of viral hepatitis distinguished by its epidemiology and clinical presentation, with “vaccine,” from the Latin vaccinus (“pertaining to cows”) referring historically to Edward Jenner’s use of cowpox material to prevent smallpox. The modern concept of a hepatitis A vaccine emerged in the late 20th century following the isolation of HAV and the development of cell‑culture techniques for virus inactivation.
Characteristics
-
Composition:
- Inactivated (killed) vaccines: Whole HAV particles chemically inactivated (e.g., with formaldehyde).
- Recombinant vaccines: Purified HAV capsid protein (VP1) expressed in yeast or other expression systems.
-
Dosage schedule:
- Primary series: Two doses administered 6–12 months apart.
- In certain rapid‑protection protocols, an accelerated schedule (0, 7, and 21–30 days) may be employed, followed by a booster at 12 months.
-
Efficacy:
- Clinical trials report seroconversion rates >95 % after the second dose.
- Protective antibody titers (anti‑HAV IgG) persist for at least 15–20 years in most recipients.
-
Safety profile:
- Common adverse events are mild and include injection‑site pain, erythema, and low‑grade fever.
- Serious adverse reactions are rare; no consistent causal link to severe events has been established.
-
Regulatory status:
- Licensed by major health authorities (e.g., U.S. FDA, European Medicines Agency) and included in the World Health Organization’s list of prequalified vaccines.
Related Topics
- Hepatitis A virus (HAV)
- Acute viral hepatitis
- Inactivated vaccine technology
- Recombinant subunit vaccines
- Immunization schedules for travelers
- Public health strategies for hepatitis A outbreak control
- Other hepatitis vaccines (e.g., hepatitis B vaccine, hepatitis E vaccine)